Nautilus Biotechnology (NASDAQ:NAUT) reported quarterly losses of $(0.11) per share which beat the analyst consensus estimate of $(0.15) by 26.67 percent. This is a 8.33 percent increase over losses of $(0.12) per share from the same period last year.
KKR Builds On Its Investment In India’s Serentica Renewables – What’s On The Cards
KKR & Co Inc (NYSE:KKR) agrees to invest an additional $250 million in Serentica Renewables, an Indian decarbonization platform. This additional…
